Today, a total of 2 new shares were subscribed, including Junxin shares and Jindao technology on the gem; One new share is listed, which is Rongchang biology of science and innovation board.
subscription of new shares today
Junxin Co., Ltd. focuses on solid waste treatment business. Its main business includes waste incineration and power generation, sludge disposal, leachate (sewage) treatment, landfill and ash disposal.
company is a leading enterprise in the field of solid waste treatment in Hunan Province, and is also the only comprehensive collaborative treatment site for urban solid waste in Changsha, the capital of Hunan Province. In terms of treatment capacity, the company has a 63.79% share in the domestic waste incineration power generation market in Hunan Province, and ranks first in Hunan Province
Jindao technology is a leading enterprise in the field of forklift gearbox in China, has been focusing on the industrial vehicle gearbox industry, mainly engaged in the R & D, production and sales of all kinds of forklift and other industrial vehicle gearbox. Its main products include all kinds of mechanical transmission gearbox, hydraulic transmission gearbox, electric forklift gearbox, main reducer and axle box integrated products company’s main customers are forklift truck manufacturers, including Hangcha Group Co.Ltd(603298) , Guangxi Liugong Machinery Co.Ltd(000528) , JAC UnionPay, Mitsubishi Heavy Industry, Doosan forklift, etc
new shares listed today
Founded in 2008, Rongchang biology is an innovative biopharmaceutical enterprise with a global vision. Since its establishment, the company has been focusing on the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugate (ADC), antibody fusion protein, monoclonal antibody and double antibody. The company is in a leading position in China in ADC and fusion protein innovative drug track. According to the prospectus, two core products of Rongchang biology, etacept and vidicizumab, have entered the stage of commercialization after being conditionally approved in China in 202 7
The company’s earnings per share in 2020 was a loss of 1.71 yuan and earnings per share in 2021 was 0.57 yuan. It is estimated that the net profit in the first quarter of 2022 will be about -445 million yuan to -329 million yuan, a year-on-year decrease of 79.17% to 142.41%
Rongchang biology’s A-share offering price is 48 yuan / share. It is worth noting that the company has been listed in Hong Kong stocks on November 9, 2020. As of yesterday’s closing of Hong Kong stocks, Rongchang biology closed at HK $50.55/share, which has fallen below the issue price of HK $52.10/share.
